Report on TROP2 expression across tumors
Stephen V Liu shared a paper by Dan Morgenstern-Kaplan et al, on X:
“Report on TROP2 expression across tumors in The Oncologist. TROP2 high tumors often with co-mutations in TP53 (breast, CRC, panc, HCC), KRAS (panc, CRC), ARID1A and FGFR3 (urothelial), and CTNNB1 (HCC). High expression had a poor prognosis.”
Source: Stephen V Liu/X
Authors: Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris Krause, Jennifer R Ribeiro, Heng Tan, Emmanuel S Antonarakis, Emil Lou, Misako Nagasaka, Sandra Algaze, Heinz-Josef Lenz, Stephen V Liu, Balazs Halmos, Dave S B Hoon, Andreas Seeber, Patrick C Ma, Wafik S El-Deiry, Ari M Vanderwalde, Gilberto Lopes
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023